Open access
Open access
Powered by Google Translator Translator

FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs

20 Sep, 2017 | 20:50h | UTC

FDA Drug Safety Communication: FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs (free)

Commentary: Don’t Give Kayexalate With Other Oral Drugs, FDA Warns – Medscape (free registration required)

“Patients should take orally administered prescription and over-the-counter (OTC) medicines at least 3 hours before or 3 hours after sodium polystyrene sulfonate”

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.